Quan Jie, He Chun Jing, Kim Ji Yeon, Lee Jin Young, Kim Chang Jae, Jeon Young Jae, Im Chang Woo, Lee Do Kyung, Kim Ji Eun, Park Hue Jung
Department of Pain Medicine, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Department of Anesthesiology and Pain Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Biomedicines. 2024 Jun 21;12(7):1379. doi: 10.3390/biomedicines12071379.
Neuropathic pain (NP) results from lesions or diseases affecting the peripheral or central somatosensory system. However, there are currently no drugs that are particularly effective in treating this condition. SKI306X is a blend of purified extracts of three oriental herbs (Clematis mandshurica, Trichosanthes kirilowii, and Prunella vulgaris) commonly used to treat osteoarthritis for their chondroprotective effects. Chronic postischemic pain (CPIP) and spinal nerve ligation (SNL) models were created by binding the upper left ankle of mice with an O-ring for 3 h and ligating the L5 spinal nerve, respectively. Mice with allodynia were injected intraperitoneally with 0.9% normal saline (NS group) or different doses (25, 50, or 100 mg/kg) of SKI306X (SKI groups). We assessed allodynia using von Frey filaments before injection and 30, 60, 90, 120, 180, and 240 min and 24 h after injection to confirm the antiallodynic effect of SKI306X. We also measured glial fibrillary acidic protein (GFAP) levels in the spinal cord and dorsal root ganglia to confirm the change of SKI306X administration. Both models exhibited significant mechanical allodynia. The intraperitoneal injection of SKI306X significantly increased the paw withdrawal threshold in a dose-dependent manner, as the paw withdrawal threshold was significantly increased after SKI306X administration compared with at baseline or after NS administration. GFAP levels in the SKI group decreased significantly ( < 0.05). Intraperitoneal administration of SKI306X dose-dependently attenuated mechanical allodynia and decreased GFAP levels, suggesting that GFAP is involved in the antiallodynic effect of SKI306X in mice with CPIP and SNL-induced NP.
神经性疼痛(NP)由影响外周或中枢体感系统的损伤或疾病引起。然而,目前尚无对治疗该病症特别有效的药物。SKI306X是三种东方草药(东北铁线莲、瓜蒌和夏枯草)的纯化提取物混合物,这些草药常用于治疗骨关节炎,具有软骨保护作用。通过用O形环捆绑小鼠左上脚踝3小时以及分别结扎L5脊髓神经,建立慢性缺血后疼痛(CPIP)和脊髓神经结扎(SNL)模型。对有痛觉过敏的小鼠腹腔注射0.9%生理盐水(NS组)或不同剂量(25、50或100mg/kg)的SKI306X(SKI组)。在注射前以及注射后30、60、90、120、180和240分钟以及24小时,我们使用von Frey细丝评估痛觉过敏,以确认SKI306X的抗痛觉过敏作用。我们还测量了脊髓和背根神经节中的胶质纤维酸性蛋白(GFAP)水平,以确认SKI306X给药后的变化。两种模型均表现出明显的机械性痛觉过敏。腹腔注射SKI306X以剂量依赖性方式显著提高了爪部撤离阈值,因为与基线或NS给药后相比,SKI306X给药后爪部撤离阈值显著提高。SKI组中的GFAP水平显著降低(<0.05)。腹腔注射SKI306X剂量依赖性地减轻了机械性痛觉过敏并降低了GFAP水平,这表明GFAP参与了SKI306X对CPIP和SNL诱导的NP小鼠的抗痛觉过敏作用。